"Gene editing is a rapidly developing technology that represents one of the most exciting developments in medicine. These techniques will be integral to the next generation of advanced therapeutics and we welcome their potential to provide important, and potentially life-saving, treatments for patients. As with all breakthrough biotechnologies, we need to exercise caution and good stewardship in our research and development practices and ensure that work involving the genetic modification of cells takes place within the bioethical framework outlined in these principles."
Janet Lambert, CEO, The Alliance for Regenerative Medicine commenting on the release of the Alliance's Therapeutic Developers' Statement of Principles, setting forth a bioethical framework for the use of gene editing in therapeutic applications
"This is clearly part of the overall Trump administration's drug pricing plan. It's not very sexy, the idea of increasing the availability of generics, but it does seem to be the easiest to accomplish through the existing regulatory framework. And it does seem to be the one drug pricing component in the matrix, in the puzzle, that has an economic model behind it that makes sense."
Bethany Hills, an FDA and life sciences attorney and partner with New York-based Morrison & Foerster
"There are people with data and there are people with algorithms. At Numerate we developed cutting-edge algorithms. Others don't have sophisticated AI but they have a lot of data. How do you bring those two worlds together? That's the current challenge."
Brandon Allgood, the chief technical officer for the Alliance for Artificial Intelligence and Numerate Inc.